Aromatase inhibitors and tamoxifen: Where do we go from here? Commentary

Matthew P. Goetz; Charles L. Loprinzi

doi:10.1038/ncponc0955

Aromatase inhibitors and tamoxifen: Where do we go from here? Commentary

Matthew P. Goetz, Charles L. Loprinzi

Medical Oncology

Research output: Contribution to journal › Short survey › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	626-627
Number of pages	2
Journal	Nature Clinical Practice Oncology
Volume	4
Issue number	11
DOIs	https://doi.org/10.1038/ncponc0955
State	Published - Nov 2007

ASJC Scopus subject areas

Oncology

Access to Document

10.1038/ncponc0955

Cite this

@article{4a25ad6eb5e04ba09f771c7fe70e9522,

title = "Aromatase inhibitors and tamoxifen: Where do we go from here? Commentary",

author = "Goetz, {Matthew P.} and Loprinzi, {Charles L.}",

year = "2007",

month = nov,

doi = "10.1038/ncponc0955",

language = "English (US)",

volume = "4",

pages = "626--627",

journal = "Nature Clinical Practice Oncology",

issn = "1743-4254",

publisher = "Nature Publishing Group",

number = "11",

}

TY - JOUR

T1 - Aromatase inhibitors and tamoxifen

T2 - Where do we go from here? Commentary

AU - Goetz, Matthew P.

AU - Loprinzi, Charles L.

PY - 2007/11

Y1 - 2007/11

UR - http://www.scopus.com/inward/record.url?scp=35649025764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35649025764&partnerID=8YFLogxK

U2 - 10.1038/ncponc0955

DO - 10.1038/ncponc0955

M3 - Short survey

C2 - 17848931

AN - SCOPUS:35649025764

SN - 1743-4254

VL - 4

SP - 626

EP - 627

JO - Nature Clinical Practice Oncology

JF - Nature Clinical Practice Oncology

IS - 11

ER -

Aromatase inhibitors and tamoxifen: Where do we go from here? Commentary

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this